Completed × Squamous Cell Carcinoma of Head and Neck × Bevacizumab × Clear all KEYVIBE-005
Phase 2 Completed
613 enrolled
Bevacizumab/Ph 2 for Locally Advanced Head and Neck Cancer
Phase 2 Completed
3 enrolled 7 charts
Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
Phase 1/2 Completed
58 enrolled
A Phase II Trial of Cetuximab and Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer
Phase 2 Completed
48 enrolled 14 charts
Cisplatin, Bevacizumab, and Intensity-Modulated Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer
Phase 2 Completed
44 enrolled 9 charts
Bevacizumab, Docetaxel, and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer
Phase 2 Completed
30 enrolled 9 charts
Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer
Phase 1/2 Completed
66 enrolled
Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer
Phase 2 Completed
11 enrolled 7 charts
Bevacizumab, Fluorouracil, and Hydroxyurea Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer
Phase 1 Completed
39 enrolled